|
1) Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-74
|
|
|
|
2) Baumann H, Gauldie J. The acute thase response. Immunol Today. 1994; 15: 74-80
|
|
|
|
|
|
3) Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2001; 21: 1962-8
|
|
|
|
|
|
4) Hashimoto H, Kitagawa K, Hougaku H, et al. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke. 2004; 35: 1625-30
|
|
|
|
|
|
5) 高橋若生. 炎症, 特に高感度CRPと脳卒中. 医学のあゆみ. 2005; 22: 551-5
|
|
|
|
|
|
6) van Der Meer IM, de Maat MPM, Hak E, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke. 2002; 33: 2750-5
|
|
|
|
|
|
7) Agmon Y, Khandheria BK, Meissner I, et al. C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. Arch Intern Med. 2004; 164: 1781-7
|
|
|
|
|
|
8) Makita S, Nakamura M, Hiramori K. The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke. 2005; 36: 2138-42
|
|
|
|
|
|
9) Lorenz MW, Karbstein P, Markus HS, et al. High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study. Stroke. 2007; 38: 1774-9
|
|
|
|
|
|
10) Thakore AH, Guo CY, Larson MG, et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol. 2007; 99: 1598-602
|
|
|
|
|
|
11) Hoshi T, Kitagawa K, Yamagami H, et al. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke. 2005; 36: 768-72
|
|
|
|
|
|
12) van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and small-vessel disease: the Rotterdam Scan study. Circulation. 2005; 112: 900-5
|
|
|
|
|
|
13) Schmidt R, Schmidt H, MD, Pichler M, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke. 2006; 37: 2910-6
|
|
|
|
|
|
14) Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-43
|
|
|
|
|
|
15) Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. The Framingham study. Stroke. 2001; 32: 2575-9
|
|
|
|
|
|
16) Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003; 108: 166-70
|
|
|
|
|
|
17) Wakugawa Y, Kiyohara Y, Tanizaki Y, et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population. The Hisayama Study. Stroke. 2006; 37: 27-32
|
|
|
|
|
|
18) Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003; 108: 2317-22
|
|
|
|
|
|
19) Bos MJ, Schipper CM, Koudstaal PJ, et al. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation. 2006; 114: 1591-8
|
|
|
|
|
|
20) Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-9
|
|
|
|
|
|
21) Goto S. Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents. Curr Vasc Pharmacol. 2004; 2: 23-32
|
|
|
|
|
|
22) Bhakdi S, Torzewski M, Klouche M, et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 1999; 19: 2348-54
|
|
|
|
|
|
23) Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20: 2094
|
|
|
|
|
|
24) Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001; 103: 1194
|
|
|
|
|
|
25) Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 165
|
|
|
|
|
|
26) Singh U, Devaraj S, Dasu MR, et al. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol. 2006; 26: 2469-75
|
|
|
|
|
|
27) Verna S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004; 109: 2058-67
|
|
|
|
|
|
28) Fujii H, Li SH, Szmitko PE, et al. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2006; 26: 2476-82
|
|
|
|
|
|
29) Montero I, Orbe J, Varo N, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol. 2006; 47: 1369-78
|
|
|
|
|
|
30) Yaron G, Brill A, Dashevsky O, et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol. 2006; 134: 426-31
|
|
|
|
|
|
31) Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003; 289: 1799-804
|
|
|
|
|
|
32) Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: a systemic review. Arch Intern Med. 2007; 167: 31-9
|
|
|
|
|
|
33) Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352: 29-38
|
|
|
|
|
|
34) Yasunari K, Maeda K, Watanabe T, et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. Hypertension. 2004; 43: 2116-23
|
|
|
|
|
|
35) Sidhu JS, Cowan D, Kashi JC. The effects of rosiglitazone, a peroxisome proliferators-activated receptor gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003; 42: 1757-63
|
|
|
|
|
|
36) 尾崎由基男. 心血管疾患予防における抗血小板薬の内皮機能改善効果を探る. Vascular Medicine. 2006; 2: 212-9
|
|
|
|
|
37) Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006; 440: 1217-21
|
|
|
|
|